BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35116520)

  • 1. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.
    Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H
    Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review.
    Guo HP; Dang XL; Kang L; Liu C; Liu XW
    World Neurosurg; 2024 Apr; 188():161-169. PubMed ID: 38641241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.
    Shen J; Liu J
    Front Oncol; 2022; 12():1034668. PubMed ID: 36465385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
    Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
    Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.
    Du S; Fu DB; A Bota D; Kong XT
    CNS Oncol; 2024 Jun; 13(1):2345579. PubMed ID: 38722227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
    Chen J; Kinoshita T; Gururaja T; Sukbuntherng J; James D; Lu D; Whang J; Versele M; Chang BY
    Eur J Haematol; 2018 Jul; ():. PubMed ID: 30030853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review.
    Nepal G; Khurana M; Bucheli DH; Bhandari S; Joshi U; Bhagat R; Rehrig JH; Pudasainee P; Shing YK; Ortiz JF; Ojha R; Gajurel BP; Quinonez J; Ruxmohan S; Albert T; Licata S; Stien J
    Neurol Int; 2022 Jan; 14(1):99-108. PubMed ID: 35076567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
    Lionakis MS; Dunleavy K; Roschewski M; Widemann BC; Butman JA; Schmitz R; Yang Y; Cole DE; Melani C; Higham CS; Desai JV; Ceribelli M; Chen L; Thomas CJ; Little RF; Gea-Banacloche J; Bhaumik S; Stetler-Stevenson M; Pittaluga S; Jaffe ES; Heiss J; Lucas N; Steinberg SM; Staudt LM; Wilson WH
    Cancer Cell; 2017 Jun; 31(6):833-843.e5. PubMed ID: 28552327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.
    Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C
    Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon.
    Lino-Silva LS; Martínez-Villavicencio SB; Rivera-Moncada LF
    World J Clin Oncol; 2024 May; 15(5):587-590. PubMed ID: 38835851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton's tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics.
    Kozaki R; Yasuhiro T; Kato H; Murai J; Hotta S; Ariza Y; Sakai S; Fujikawa R; Yoshida T
    PLoS One; 2023; 18(3):e0282166. PubMed ID: 36897912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in the diagnosis and the treatment of primary CNS lymphoma.
    Rachdi A; Hernandez-Tost H; Herzi D; Morales-Martinez A; Hernández-Verdin I; Houillier C; Alentorn A; Hoang-Xuan K
    Rev Neurol (Paris); 2023 Jun; 179(5):481-489. PubMed ID: 37045615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma.
    Steffanoni S; Batchelor TT
    Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
    Grommes C; Pastore A; Palaskas N; Tang SS; Campos C; Schartz D; Codega P; Nichol D; Clark O; Hsieh WY; Rohle D; Rosenblum M; Viale A; Tabar VS; Brennan CW; Gavrilovic IT; Kaley TJ; Nolan CP; Omuro A; Pentsova E; Thomas AA; Tsyvkin E; Noy A; Palomba ML; Hamlin P; Sauter CS; Moskowitz CH; Wolfe J; Dogan A; Won M; Glass J; Peak S; Lallana EC; Hatzoglou V; Reiner AS; Gutin PH; Huse JT; Panageas KS; Graeber TG; Schultz N; DeAngelis LM; Mellinghoff IK
    Cancer Discov; 2017 Sep; 7(9):1018-1029. PubMed ID: 28619981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
    Bhatti M; Ayton S; Michail O; Gollop ND; Ryding A; Rushworth S; Bowles K; Geisler T; Flather M
    Thromb Res; 2019 Jul; 179():64-68. PubMed ID: 31082751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.